{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:54:33Z","timestamp":1789764873455,"version":"4.0.1"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Africa Research Excellence Fund Research Development Fellowship","award":["AREF-318-ABDUL-F-C0882"],"award-info":[{"award-number":["AREF-318-ABDUL-F-C0882"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PANGEA","award":["OPP1175094"],"award-info":[{"award-number":["OPP1175094"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI147331-01)"],"award-info":[{"award-number":["R01AI147331-01)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wellcome Trust Senior Fellowship in Clinical Science","award":["WT108082AIA"],"award-info":[{"award-number":["WT108082AIA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Due to the high prevalence of resistance to NNRTI-based ART since 2018, consolidated recommendations from the WHO have indicated dolutegravir as the preferred drug of choice for HIV treatment globally. There is a paucity of resistance outcome data from HIV-1 non-B subtypes circulating across West Africa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>We characterized the mutational profiles of persons living with HIV from a cross-sectional cohort in North-East Nigeria failing a dolutegravir-based ART regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>WGS of plasma samples collected from 61 HIV-1-infected participants following virological failure of dolutegravir-based ART were sequenced using the Illumina platform. Sequencing was successfully completed for samples from 55 participants. Following quality control, 33 full genomes were analysed from participants with a median age of 40 years and median time on ART of 9 years. HIV-1 subtyping was performed using SNAPPy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Most participants had mutational profiles reflective of exposure to previous first- and second-line ART regimens comprised NRTIs and NNRTIs. More than half of participants had one or more drug resistance-associated mutations (DRMs) affecting susceptibility to NRTIs (17\/33; 52%) and NNRTIs (24\/33; 73%). Almost a quarter of participants (8\/33; 24.4%) had one or more DRMs affecting tenofovir susceptibility. Only one participant, infected with HIV-1 subtype G, had evidence of DRMs affecting dolutegravir susceptibility\u2014this was characterized by the T66A, G118R, E138K and R263K mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study found a low prevalence of resistance to dolutegravir; the data are therefore supportive of the continual rollout of dolutegravir as the primary first-line regimen for ART-naive participants and the preferred switch to second-line ART across the region. However, population-level, longer-term data collection on dolutegravir outcomes are required to further guide implementation and policy action across the region.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad195","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T15:28:15Z","timestamp":1687879695000},"page":"2000-2007","source":"Crossref","is-referenced-by-count":27,"title":["Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-8264","authenticated-orcid":false,"given":"Adam","family":"Abdullahi","sequence":"first","affiliation":[{"name":"Department of Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) , Cambridge , UK"},{"name":"Department of Medicine, University of Cambridge , Cambridge , UK"},{"name":"Institute of Human Virology Nigeria , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Musa","family":"Kida","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Clinical Immunology, University of Maiduguri , Borno , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar Abdullahi","family":"Maina","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Maiduguri , Borno , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina Husaini","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Federal Medical Centre , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mshelia","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Clinical Immunology, University of Maiduguri , Borno , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Wisso","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullahi","family":"Adamu","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Maiduguri , Borno , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Ezenwa","family":"Onyemata","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Edun","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Yusuph","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Clinical Immunology, University of Maiduguri , Borno , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-2940","authenticated-orcid":false,"given":"Sani H","family":"Aliyu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Addenbrooke\u2019s Hospital, Cambridge University Hospitals NHS Foundation Trust , Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Charurat","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine , Baltimore , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alash\u2019le","family":"Abimiku","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Abeler-Dorner","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Big Data Institute, University of Oxford , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Fraser","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Big Data Institute, University of Oxford , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bonsall","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Big Data Institute, University of Oxford , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PANGEA consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Abeler-D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ayles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bonsall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Essex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Golubchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Herbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kagaayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairam","family":"Lingappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikhulile","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Novitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thumbi","family":"Ndung'u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rambaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ratmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Seeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deogratius","family":"Ssemwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tanser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulio","family":"D'Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Essex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Golubchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Herbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Leigh-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairam","family":"Lingappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Novitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Paton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ratmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deogratius","family":"Ssemwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tanser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Kemp","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) , Cambridge , UK"},{"name":"Department of Medicine, University of Cambridge , Cambridge , UK"},{"name":"Nuffield Department of Medicine, Big Data Institute, University of Oxford , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-1808","authenticated-orcid":false,"given":"Ravindra K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) , Cambridge , UK"},{"name":"Department of Medicine, University of Cambridge , Cambridge , UK"},{"name":"Africa Health Research Institute , Durban , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"2023080202255057500_dkad195-B1","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"2023080202255057500_dkad195-B2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023080202255057500_dkad195-B3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eclinm.2019.03.006","article-title":"Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa, 2000\u20132016: a pooled sequence analysis","volume":"9","author":"Chimukangara B, Lessells RJ, Rhee S-Y","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2023080202255057500_dkad195-B4","author":"WHO","year":"2019"},{"key":"2023080202255057500_dkad195-B5","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1097\/QAD.0000000000003068","article-title":"Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial","volume":"35","author":"Jamieson","year":"2021","journal-title":"AIDS"},{"key":"2023080202255057500_dkad195-B6","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/S2352-3018(18)30331-X","article-title":"Dolutegravir in sub-Saharan Africa: context is crucial","volume":"6","author":"Dorward","year":"2019","journal-title":"Lancet HIV"},{"key":"2023080202255057500_dkad195-B7","author":"Federal Ministry of Health Abuja Nigeria","year":"2020"},{"key":"2023080202255057500_dkad195-B8","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"2023080202255057500_dkad195-B9","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"2023080202255057500_dkad195-B10","doi-asserted-by":"crossref","first-page":"e0000826","DOI":"10.1371\/journal.pgph.0000826","article-title":"HIV-1 integrase resistance associated mutations and the use of dolutegravir in sub-Saharan Africa: a systematic review and meta-analysis","volume":"2","author":"Semengue","year":"2022","journal-title":"PLOS Glob Public Heal"},{"key":"2023080202255057500_dkad195-B11","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/cid\/cix1108","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor\u2013based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis","volume":"66","author":"Stockdale","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023080202255057500_dkad195-B12","doi-asserted-by":"crossref","first-page":"e00382-20","DOI":"10.1128\/JCM.00382-20","article-title":"A comprehensive genomics solution for HIV surveillance and clinical monitoring in low-income settings","volume":"58","author":"Bonsall","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2023080202255057500_dkad195-B13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/molbev\/msx304","article-title":"PHYLOSCANNER: inferring transmission from within- and between-host pathogen genetic diversity","volume":"35","author":"Wymant","year":"2018","journal-title":"Mol Biol Evol"},{"key":"2023080202255057500_dkad195-B14","first-page":"52","article-title":"HIV sequence databases","volume":"5","author":"Kuiken","year":"2003","journal-title":"AIDS Rev"},{"key":"2023080202255057500_dkad195-B15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","article-title":"IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era","volume":"37","author":"Minh","year":"2020","journal-title":"Mol Biol Evol"},{"key":"2023080202255057500_dkad195-B16","doi-asserted-by":"crossref","first-page":"vez050","DOI":"10.1093\/ve\/vez050","article-title":"SNAPPy: a snakemake pipeline for scalable HIV-1 subtyping by phylogenetic pairing","volume":"5","author":"Ara\u00fajo","year":"2019","journal-title":"Virus Evol"},{"key":"2023080202255057500_dkad195-B17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/jac\/dkab385","article-title":"Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria","volume":"77","author":"El Bouzidi","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/aid.2010.0050","article-title":"Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy","volume":"27","author":"Chaplin","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023080202255057500_dkad195-B19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","article-title":"The impact of HIV-1 drug escape on the global treatment landscape","volume":"26","author":"Collier","year":"2019","journal-title":"Cell Host Microbe"},{"key":"2023080202255057500_dkad195-B20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/infdis\/jiz631","article-title":"Human immunodeficiency virus-1 viral load is elevated in individuals with reverse-transcriptase mutation M184V\/I during virological failure of first-line antiretroviral therapy and is associated with compensatory mutation L74I","volume":"222","author":"Gregson","year":"2020","journal-title":"J Infect Dis"},{"key":"2023080202255057500_dkad195-B21","doi-asserted-by":"crossref","first-page":"e00269-22","DOI":"10.1128\/mbio.00269-22","article-title":"HIV-1 evolutionary dynamics under nonsuppressive antiretroviral therapy","volume":"13","author":"Kemp","year":"2022","journal-title":"mBio"},{"key":"2023080202255057500_dkad195-B22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(16)30469-8","article-title":"Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study","volume":"17","author":"Gregson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023080202255057500_dkad195-B23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"TenoRes Study Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023080202255057500_dkad195-B24","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/S2352-3018(20)30172-7","article-title":"Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study","volume":"7","author":"Gupta-Wright","year":"2020","journal-title":"Lancet HIV"},{"key":"2023080202255057500_dkad195-B25","doi-asserted-by":"crossref","first-page":"e02036-20","DOI":"10.1128\/mBio.02036-20","article-title":"In vivo emergence of a novel protease inhibitor resistance signature in HIV-1 matrix","volume":"11","author":"Datir","year":"2020","journal-title":"mBio"},{"key":"2023080202255057500_dkad195-B26","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1038\/s41467-020-19801-x","article-title":"Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase","volume":"11","author":"Siedner","year":"2020","journal-title":"Nat Commun"},{"key":"2023080202255057500_dkad195-B27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2023080202255057500_dkad195-B28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B29","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023080202255057500_dkad195-B30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2023080202255057500_dkad195-B31","doi-asserted-by":"crossref","first-page":"e16813","DOI":"10.1097\/MD.0000000000016813","article-title":"DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients","volume":"98","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2023080202255057500_dkad195-B32","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jac\/dkaa019","article-title":"M184V\/I does not impact the efficacy of abacavir\/lamivudine\/dolutegravir use as switch therapy in virologically suppressed patients","volume":"75","author":"Jary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B33","doi-asserted-by":"crossref","first-page":"102779","DOI":"10.1016\/j.ebiom.2020.102779","article-title":"Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)","volume":"55","author":"De Miguel","year":"2020","journal-title":"eBioMedicine"},{"key":"2023080202255057500_dkad195-B34","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/cid\/cit933","article-title":"High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy","volume":"58","author":"Gupta","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023080202255057500_dkad195-B35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/cix015","article-title":"Virological outcomes of second-line protease inhibitor\u2013based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis","volume":"64","author":"Collier","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023080202255057500_dkad195-B36","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/jac\/dku199","article-title":"Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity","volume":"69","author":"Mespl\u00e8de","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B37","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B38","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkw071","article-title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","volume":"71","author":"Brenner","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B39","doi-asserted-by":"crossref","first-page":"ofy329","DOI":"10.1093\/ofid\/ofy329","article-title":"Development of the R263K mutation to dolutegravir in an HIV-1 subtype D virus harboring 3 class-drug resistance","volume":"6","author":"Ahmed","year":"2019","journal-title":"Open forum Infect Dis"},{"key":"2023080202255057500_dkad195-B40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4102\/sajhivmed.v20i1.885","article-title":"A case report of untreatable HIV infection in Harare, Zimbabwe","volume":"20","author":"Chimbetete","year":"2019","journal-title":"South Afr J HIV Med"},{"key":"2023080202255057500_dkad195-B41","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1089\/aid.2017.0205","article-title":"Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda","volume":"34","author":"Ndashimye","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023080202255057500_dkad195-B42","first-page":"1062","article-title":"Case report: emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy","volume":"21","author":"Mahomed","year":"2020","journal-title":"South African J HIV Med"},{"key":"2023080202255057500_dkad195-B43","doi-asserted-by":"crossref","first-page":"e0138622","DOI":"10.1128\/aac.01386-22","article-title":"The G118R plus R263K combination of integrase mutations associated with dolutegravir-based treatment failure reduces HIV-1 replicative capacity and integration","volume":"67","author":"Xiao","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202255057500_dkad195-B44","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/jac\/dkab004","article-title":"Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings","volume":"76","author":"Semengue","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B45","first-page":"1575","article-title":"High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment","volume":"75","author":"El Bouzidi","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/QAD.0000000000003413","article-title":"Prevalence of HIV drug resistance in Nigeria: results from a cross-sectional, population-based survey of Nigerian adults with unsuppressed viral load","volume":"37","author":"Aliyu","year":"2023","journal-title":"AIDS"},{"key":"2023080202255057500_dkad195-B47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0b013e3181b06125","article-title":"Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria","volume":"52","author":"Hawkins","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023080202255057500_dkad195-B48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/505711","article-title":"Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level","volume":"194","author":"Parikh","year":"2006","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"2023080202255057500_dkad195-B49","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/jit107","article-title":"Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings","volume":"207","author":"Hosseinipour","year":"2013","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"2023080202255057500_dkad195-B50","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1093\/infdis\/jit112","article-title":"Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy\u2014implications for sustained efficacy of ART in resource-limited settings","volume":"207","author":"Hill","year":"2013","journal-title":"J Infect Dis"},{"key":"2023080202255057500_dkad195-B51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/infdis\/jiab382","article-title":"Monitoring emerging human immunodeficiency virus drug resistance in sub-Saharan Africa in the era of dolutegravir","volume":"225","author":"da Silva","year":"2022","journal-title":"J Infect Dis"},{"key":"2023080202255057500_dkad195-B52","doi-asserted-by":"crossref","first-page":"100231","DOI":"10.1016\/j.eclinm.2019.12.001","article-title":"Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa","volume":"18","author":"Villa","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2023080202255057500_dkad195-B53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2023080202255057500_dkad195-B54","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/jac\/dkz264","article-title":"An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy","volume":"74","author":"Geretti","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023080202255057500_dkad195-B55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/QAI.0000000000002918","article-title":"Disengagement from HIV care and failure of second-line therapy in Nigeria: a retrospective cohort study, 2005\u20132017","volume":"90","author":"El Bouzidi","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023080202255057500_dkad195-B56","author":"WHO","year":"2022"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/8\/2000\/50967388\/dkad195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/8\/2000\/50967388\/dkad195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T02:27:21Z","timestamp":1690943241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/8\/2000\/7208628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,27]]},"published-print":{"date-parts":[[2023,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad195","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,6,27]]}}}